Bainian Yihao Nabs 150 million Yuan in Series A Funding to Set Up New Manufacturing Bases

On April 8，2019, vcbeat.com learned that Chengdu Bainian Yihao Pharmaceutical Technology Co., LTD.（Bainian Yihao）raised 150 million Yuan in Series A funding. The round was led by DT Capital Partners, Pku V-ming Investment, Chengdu Tianfu International Bio-town Investment & Development and Guangzhou Kejin Lifeng Equity Investment Partnership.

Those funds are mainly used to set up new manufacturing bases. As far as we know, its next round has a number of well-known investors who have locked in shares previously.

Bainian Yihao, founded in 2017, with its target of being a new drug research and development institution through biomedical, is focused on new drug researches and developments based on the CAR-T cells therapies, immune therapies, gene therapies, stem cell therapies and a tiny molecule targeted therapies drugs. Its manufacturing center, Bainian Yihao Institute has formally settled in Chengdu Tianfu International Bio-town in January 2019.

Bainian Yihao and Sichuan University State Key Laboratory of Biological have reached exclusive cooperation. It set up 7 technology pipeline to provide the technology platform for project transformation, including 6 centers respectively research and develop vaccines and cells, including CAR – T cells (with a complete chain of CAR-T cells from development to clinical trials), DC vaccines, stem cells, gene vaccines, bacterial vaccines, mRNA vaccines. At present, more than 90 projects have been involved.

It is reported that the CAR – T and other project orders of Bainian Yihao have reached 180 million yuan, which have been transferred to two large listed pharmaceutical companies.

Detong capital is a leading private equity investment company in China, focusing on the fields of consumer, healthcare, and intelligent manufacturing. Detong Capital invests high-growth companies with huge market opportunities, excellent management team and clear operation pattern. Detong Capital has more than 10 billion RMB under management. Its major investors include funds of many provincial and municipal governments and financial institutions. It also has set up industrial merger funds with a number of leading listed companies.

Pku V-ming Investment Holding co., LTD is controlled by one of the three industrial groups of Peking University, Beijing Sinobioway Group Co., Ltd(referred to as Weiming group). V-ming is a large investment holding company jointly invested by well-known listed state-owned enterprises. This international company aims to achieve rapid appreciation. It focuses on providing global finance and public service of an international investment bank for Chinese high-growth companies. The paid-in registered capital of the company is 200 million yuan.

Chengdu Tianfu International Bio-town Investment & Development was established on May 10, 2016, with a registered capital of 3 billion yuan. It is responsible for the infrastructure construction, supporting construction, industrial investment, and operation of Chengdu Tianfu International Bio-town. It has participated in the establishment of China (Sichuan) Biomedical Industry Fund.